Zoledronic acid shows promise in preserving bone strength after spinal cord injury
NCT ID NCT02325414
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study looked at whether a single dose of zoledronic acid, a drug already used for osteoporosis, could prevent the rapid bone loss that often happens after a spinal cord injury. Researchers followed 60 adults who had recently been injured and could not walk independently. They measured changes in bone density and strength over time to see if the treatment helped protect the bones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Rehabilitation Institute of Chicago
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.